Kolexia
Eisenmann Jean-Claude Médecine interne
Eisenmann Jean-Claude
Médecine interne
Hôpital Hasenrain
Mulhouse, France
94 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Lymphomes Leucémies Tumeurs à plasmocytes Leucémie à tricholeucocytes Neutropénie Seconde tumeur primitive Maladie de Hodgkin Lymphome folliculaire

Collaborateurs

Voir plus
Drenou Bernard
Drenou Bernard
Hôpital Emile Muller, Mulhouse, France
Ojeda Uribe Mario
Ojeda Uribe Mario
Hôpital Emile Muller, Mulhouse, France
Arkam Yazid
Arkam Yazid
Hôpital Emile Muller, Mulhouse, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France

Industries

Voir plus
A+A
196 collaboration(s)
Dernière en 2023
IQVIA
154 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
87 collaboration(s)
Dernière en 2023
All Global
20 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Blood   23 novembre 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Leukemia   14 octobre 2021
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
Blood advances   14 mai 2021
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
Blood   05 novembre 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Blood cancer journal   27 mai 2020